Cenexi turnaround execution risk
Cenexi's performance has been below expectations, with losses persisting due to remediation activities and equipment breakdowns. Achieving positive EBITDA by Q3 FY26 is uncertain.
high · management_commentaryGland Pharma Limited — Q4 FY25
Gland Pharma's Q4 FY25 consolidated revenue was INR 1,424.9 crore with EBITDA of INR 347.5 crore (24% margin, +100bps YoY).
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
U.S. tariff impact on generics
The U.S. administration's reciprocal tariffs create uncertainty for Indian pharma companies. While management expects minimal impact on generics, the situation remains fluid.
medium · analyst_questionROW market tender losses
The ROW segment saw a 14% revenue decline in Q4 due to tender misses and softer offtake. Recovery depends on re-engaging local partners and executing a non-Enoxa strategy.
medium · management_commentaryCenexi capital allocation concerns
Analysts questioned the return on invested capital for Cenexi, given the high acquisition cost and additional capex. Management's target of 18% EBITDA on $300M revenue may still yield suboptimal ROCE.
medium · analyst_question